ONCOGENEX PHARMACEUTICALS IN's ticker is OGXI and the CUSIP is 68230A106. A total of 55 filers reported holding ONCOGENEX PHARMACEUTICALS IN in Q3 2015. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2017 | $6,000 | -25.0% | 17,281 | -0.2% | 0.00% | – |
| Q1 2017 | $8,000 | -11.1% | 17,315 | +0.2% | 0.00% | – |
| Q4 2016 | $9,000 | -10.0% | 17,280 | -13.8% | 0.00% | – |
| Q3 2016 | $10,000 | -58.3% | 20,037 | -15.9% | 0.00% | – |
| Q2 2016 | $24,000 | +20.0% | 23,817 | -19.6% | 0.00% | – |
| Q1 2016 | $20,000 | -50.0% | 29,616 | -10.7% | 0.00% | – |
| Q4 2015 | $40,000 | -36.5% | 33,174 | +17.8% | 0.00% | – |
| Q3 2015 | $63,000 | -20.3% | 28,151 | -17.5% | 0.00% | – |
| Q2 2015 | $79,000 | +19.7% | 34,116 | +10.4% | 0.00% | – |
| Q1 2015 | $66,000 | -62.1% | 30,900 | -59.3% | 0.00% | – |
| Q4 2014 | $174,000 | -45.5% | 75,997 | -36.5% | 0.00% | – |
| Q3 2014 | $319,000 | +87.6% | 119,601 | +162.1% | 0.00% | – |
| Q2 2014 | $170,000 | -67.2% | 45,634 | +3.3% | 0.00% | – |
| Q1 2014 | $519,000 | – | 44,193 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 396,104 | $400,000 | 0.42% |
| Ancora Advisors LLC | 50,865 | $51,000 | 0.01% |
| EAGLE GLOBAL ADVISORS LLC | 145,710 | $146,000 | 0.00% |
| Acrospire Investment Management LLC | 5,200 | $5,000 | 0.00% |
| A.R.T. Advisors, LLC | 57,954 | $57,000 | 0.00% |
| Renaissance Technologies | 876,100 | $876,000 | 0.00% |
| PRELUDE CAPITAL MANAGEMENT, LLC | 4,600 | $5,000 | 0.00% |
| Cutler Group LLC / CA | 11,048 | $11,000 | 0.00% |
| PANAGORA ASSET MANAGEMENT INC | 133,846 | $134,000 | 0.00% |
| PRICE T ROWE ASSOCIATES INC /MD/ | 46,100 | $46,000 | 0.00% |